Item 8. Financial Statements and Supplementary Data.

163K characters. Original on sec.gov · Markdown

Item 8. Financial Statements and Supplementary Data.

| --- | --- |

IDEX CORPORATION

CONSOLIDATED BALANCE SHEETS


	As of December 31,
	2012			2011
	(In thousands except share and per share amounts)
ASSETS
Current assets
Cash and cash equivalents	$	318,864		$	230,259
Receivables — net		256,095			252,845
Inventories		234,950			254,258
Other current assets		71,956			51,799

Total current assets		881,865			789,161
Property, plant and equipment — net		219,161			213,717
Goodwill		1,321,727			1,431,366
Intangible assets — net		341,372			382,222
Other noncurrent assets		21,265			19,641

Total assets	$	2,785,390		$	2,836,107

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities
Trade accounts payable	$	117,341		$	110,977
Accrued expenses		150,176			130,696
Short-term borrowings		7,335			2,444
Dividends payable		16,575			14,161

Total current liabilities		291,427			258,278
Long-term borrowings		779,241			806,366
Deferred income taxes		121,349			142,482
Other noncurrent liabilities		128,375			115,846

Total liabilities		1,320,392			1,322,972

Commitments and contingencies (Note 8)
Shareholders’ equity
Preferred stock:
Authorized: 5,000,000 shares, $.01 per share par value; Issued: none		—			—
Common stock:
Authorized: 150,000,000 shares, $.01 per share par value; Issued: 87,732,405 shares at December 31, 2012 and 85,968,630 shares at December 31, 2011		877			860
Additional paid-in capital		550,682			490,128
Retained earnings		1,113,541			1,142,412
Treasury stock at cost: 5,005,518 shares at December 31, 2012 and 2,734,747 shares at December 31, 2011		(156,699	)		(64,796	)
Accumulated other comprehensive loss		(43,403	)		(55,469	)

Total shareholders’ equity		1,464,998			1,513,135

Total liabilities and shareholders’ equity	$	2,785,390		$	2,836,107

See Notes to Consolidated Financial Statements.

IDEX CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS


	For the Years Ended December 31,
	2012		2011			2010
	(In thousands except per share amounts)
Net sales	$	1,954,258	$	1,838,451		$	1,513,073
Cost of sales		1,150,558		1,099,778			894,590

Gross profit		803,700		738,673			618,483
Selling, general and administrative expenses		444,490		421,703			358,272
Asset impairments		198,519		—			—
Restructuring expenses		32,473		12,314			11,095

Operating income		128,218		304,656			249,116
Other income (expense) — net		236		(1,443	)		(1,092	)
Interest expense		42,250		29,332			16,150

Income before income taxes		86,204		273,881			231,874
Provision for income taxes		48,574		80,024			74,774

Net income	$	37,630	$	193,857		$	157,100

Earnings per common share:
Basic earnings per common share	$	0.45	$	2.34		$	1.93

Diluted earnings per common share	$	0.45	$	2.32		$	1.90

Share data:
Basic weighted average common shares outstanding		82,689		82,145			80,466
Diluted weighted average common shares outstanding		83,641		83,543			81,983

See Notes to Consolidated Financial Statements.

IDEX CORPORATION

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME


	For the Years Ended December 31,
	2012			2011			2010
	(In thousands)
Net income	$	37,630		$	193,857		$	157,100
Other comprehensive income (loss)
Gains (losses) and reclassification adjustments for derivatives, net of tax		4,780			(20,254	)		(14,210	)
Pension and other postretirement adjustments, net of tax		(7,159	)		(8,398	)		(2,830	)
Cumulative translation adjustment		14,445			(14,108	)		(21,097	)

Comprehensive income	$	49,696		$	151,097		$	118,963

See Notes to Consolidated Financial Statements.

IDEX CORPORATION

CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY


	Common Stock and Additional Paid-In Capital			Retained Earnings			Accumulated Other Comprehensive Income (Loss)									Treasury Stock			Total Shareholders’ Equity
			Cumulative Translation Adjustment			Retirement Benefits Adjustments			Cumulative Unrealized Gain (Loss) on Derivatives
	(In thousands except share and per share amounts)
Balance, December 31, 2009	$	402,405		$	896,977		$	59,399		$	(27,258	)	$	(6,713	)	$	(56,706	)	$	1,268,104

Net income		—			157,100			—			—			—			—			157,100
Cumulative translation adjustment		—			—			(21,097	)		—			—			—			(21,097	)
Net change in retirement obligations (net of tax expense of $1.7 million)		—			—			—			(2,830	)		—			—			(2,830	)
Net change on derivatives designated as cash flow hedges (net of tax benefit of $11.9 million)		—			—			—			—			(14,210	)		—			(14,210	)
Issuance of 1,222,274 shares of common stock from issuance of unvested shares, exercise of stock options and deferred compensation plans		22,354			—			—			—			—			—			22,354
Share-based compensation		17,358			—			—			—			—			—			17,358
Unvested shares surrendered for tax withholding		—			—			—			—			—			(2,082	)		(2,082	)
Cash dividends declared — $.60 per common share outstanding		—			(49,037	)		—			—			—			—			(49,037	)

Balance, December 31, 2010	$	442,117		$	1,005,040		$	38,302		$	(30,088	)	$	(20,923	)	$	(58,788	)	$	1,375,660

Net income		—			193,857			—			—			—			—			193,857
Cumulative translation adjustment		—			—			(14,108	)		—			—			—			(14,108	)
Net change in retirement obligations (net of tax benefit of $4.2 million)		—			—			—			(8,398	)		—			—			(8,398	)
Net change on derivatives designated as cash flow hedges (net of tax benefit of $12.5 million)		—			—			—			—			(20,254	)		—			(20,254	)
Issuance of 1,596,145 shares of common stock from issuance of unvested shares, exercise of stock options and deferred compensation plans		37,621			—			—			—			—			—			37,621
Share-based compensation		11,250			—			—			—			—			—			11,250
Unvested shares surrendered for tax withholding		—			—			—			—			—			(6,008	)		(6,008	)
Cash dividends declared — $.68 per common share outstanding		—			(56,485	)		—			—			—			—			(56,485	)

Balance, December 31, 2011	$	490,988		$	1,142,412		$	24,194		$	(38,486	)	$	(41,177	)	$	(64,796	)	$	1,513,135

Net income		—			37,630			—			—			—			—			37,630
Cumulative translation adjustment		—			—			14,445			—			—			—			14,445
Net change in retirement obligations (net of tax benefit of $1.6 million)		—			—			—			(7,159	)		—			—			(7,159	)
Net change on derivatives designated as cash flow hedges (net of tax of $2.8 million)		—			—			—			—			4,780			—			4,780
Issuance of 1,826,977 shares of common stock from issuance of unvested shares, exercise of stock options and deferred compensation plans		49,721			—			—			—			—			—			49,721
Repurchase of 2,182,946 shares of common stock		—			—			—			—			—			(89,563	)		(89,563	)
Share-based compensation		10,850			—			—			—			—			—			10,850
Unvested shares surrendered for tax withholding		—			—			—			—			—			(2,340	)		(2,340	)
Cash dividends declared — $.80 per common share outstanding		—			(66,501	)		—			—			—			—			(66,501	)

Balance, December 31, 2012	$	551,559		$	1,113,541		$	38,639		$	(45,645	)	$	(36,397	)	$	(156,699	)	$	1,464,998

See Notes to Consolidated Financial Statements.

IDEX CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS


	For The Years Ended December 31,
	2012			2011			2010
	(In thousands)
Cash flows from operating activities
Net income	$	37,630		$	193,857		$	157,100
Adjustments to reconcile net income to net cash provided by operating activities:
Loss (gain) on sale of fixed assets		—			(2,831	)		12
Asset impairments		198,519			—			—
Depreciation and amortization		36,827			36,882			32,367
Amortization of intangible assets		41,485			35,504			25,741
Amortization of debt issuance expenses		1,685			1,263			547
Share-based compensation expense		13,102			12,076			17,358
Deferred income taxes		(37,229	)		(3,576	)		(7,336	)
Excess tax benefit from share-based compensation		(4,474	)		(5,298	)		(3,457	)
Non-cash interest expense associated with forward starting swaps		7,637			3,570			—
Forward starting interest rate contract settlement		—			(38,707	)		(30,970	)
Changes in (net of the effect from acquisitions):
Receivables		12,747			(16,488	)		(22,162	)
Inventories		23,799			(607	)		(26,651	)
Other current assets		(12,127	)		877			(2,985	)
Trade accounts payable		(1,376	)		(8,645	)		21,432
Accrued expenses		9,944			7,411			17,941
Other — net		(1,989	)		1,953			5,540

Net cash flows provided by operating activities		326,180			217,241			184,477
Cash flows from investing activities
Purchases of property, plant and equipment		(35,807	)		(35,175	)		(31,740	)
Acquisition of businesses, net of cash acquired		(68,930	)		(443,634	)		(91,286	)
Proceeds from fixed asset disposals		—			12,651			720
Other — net		(529	)		(3,379	)		—

Net cash flows used in investing activities		(105,266	)		(469,537	)		(122,306	)
Cash flows from financing activities
Borrowings under revolving facilities and credit facilities for acquisitions		35,000			365,000			53,866
Borrowings under revolving facilities		94,479			471,222			—
Borrowings under credit facilities		—			1,890			7,685
Proceeds from issuance of 4.2% Senior Notes		—			349,125			—
Proceeds from issuance of 2.58% Senior Euro Notes		—			—			96,762
Proceeds from issuance of 4.5% Senior Notes		—			—			298,427
Payments under revolving facilities, credit facilities and term loan		(158,825	)		(906,115	)		(331,632	)
Debt issuance costs		—			(5,451	)		(2,685	)
Dividends paid		(64,087	)		(54,613	)		(46,334	)
Proceeds from stock option exercises		45,771			33,064			18,057
Excess tax benefit from share-based compensation		4,474			5,298			3,457
Purchase of common stock		(89,563	)		—			—
Unvested shares surrendered for tax withholding		(2,340	)		(6,008	)		(2,082	)
Other		(1,394	)		—			—

Net cash flows (used in) provided by financing activities		(136,485	)		253,412			95,521
Effect of exchange rate changes on cash and cash equivalents		4,176			(5,993	)		3,918

Net increase (decrease) in cash		88,605			(4,877	)		161,610
Cash and cash equivalents at beginning of year		230,259			235,136			73,526

Cash and cash equivalents at end of period	$	318,864		$	230,259		$	235,136

Supplemental cash flow information
Cash paid for:
Interest	$	32,639		$	27,749		$	16,776
Income taxes		87,603			66,087			73,867
Significant non-cash activities:
Contingent consideration for acquisition		8,370			3,000			—
Debt acquired with acquisition of business		4,680			1,400			758

See Notes to Consolidated Financial Statements.

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1.	Significant Accounting Policies

Business

IDEX is an applied solutions company specializing in fluid and metering technologies, health and science technologies, and fire, safety and other diversified products built to its customers’ specifications. Its products are sold in niche markets to a wide range of industries throughout the world. The Company’s products include industrial pumps, compressors, flow meters, injectors and valves, and related controls for use in a wide variety of process applications; precision fluidics solutions, including pumps, valves, degassing equipment, corrective tubing, fittings, and complex manifolds, precision photonic solutions, optical filters and specialty medical equipment and devices used in life science applications; precision-engineered equipment for dispensing, metering and mixing paints; refinishing equipment; and engineered products for industrial and commercial markets, including fire and rescue, transportation equipment, oil and gas, electronics, and communications. These activities are grouped into three reportable segments: Fluid & Metering Technologies, Health & Science Technologies and Fire & Safety/Diversified Products.

Principles of Consolidation

The consolidated financial statements include the Company and its subsidiaries. All intercompany transactions and accounts have been eliminated.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The principal areas of estimation reflected in the financial statements are revenue recognition, sales returns and allowances, allowance for doubtful accounts, inventory valuation, recoverability of long-lived assets, income taxes, product warranties, derivatives, contingencies and litigation, insurance-related items, impairment charges, share-based compensation, defined benefit retirement plans and purchase accounting related to acquisitions.

Revenue Recognition

The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred, the sales price is fixed or determinable, and collectability of the sales price is reasonably assured. For product sales, delivery does not occur until the products have been shipped and risk of loss has been transferred to the customer. Revenue from services is recognized when the services are provided or ratably over the contract term. Some arrangements with customers may include multiple deliverables, including the combination of products and services. In such cases the Company has identified these as separate elements in accordance with ASC 605-25 and recognizes revenue consistent with the policy for each separate element based on the relative selling price method. Revenues from certain long-term contracts are recognized on the percentage-of-completion method. Percentage-of-completion is measured principally by the percentage of costs incurred to date for each contract to the estimated total costs for such contract at completion. Provisions for estimated losses on uncompleted long-term contracts are made in the period in which such losses are determined. Due to uncertainties inherent in the estimation process, it is reasonably possible that completion costs, including those arising from contract penalty provisions and final contract settlements, will be revised in the near-term. Such revisions to costs and income are recognized in the period in which the revisions are determined.

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The Company records allowances for discounts, product returns and customer incentives at the time of sale as a reduction of revenue as such allowances can be reliably estimated based on historical experience and known trends. The Company also offers product warranties and accrues its estimated exposure for warranty claims at the time of sale based upon the length of the warranty period, warranty costs incurred and any other related information known to the Company.

Shipping and Handling Costs

Shipping and handling costs are included in cost of sales and are recognized as a period expense during the period in which they are incurred.

Advertising Costs

Advertising costs of $15.3 million, $13.4 million and $11.0 million for 2012, 2011 and 2010, respectively, are expensed as incurred.

Cash and Cash Equivalents

The Company considers all highly liquid instruments purchased with an original maturity of 90 days or less to be cash and cash equivalents.

Allowance for Doubtful Accounts

The Company maintains allowances for doubtful accounts for estimated losses as a result of customer’s inability to make required payments. Management evaluates the aging of the accounts receivable balances, the financial condition of its customers, historical trends and the time outstanding of specific balances to estimate the amount of accounts receivables that may not be collected in the future and records the appropriate provision.

Inventories

The Company states inventories at the lower of cost or market. Cost, which includes material, labor, and factory overhead, is determined on a FIFO basis. We make adjustments to reduce the cost of inventory to its net realizable value, if required, at the business unit level for estimated excess, obsolescence or impaired balances. Factors influencing these adjustments include changes in market demand, product life cycle and engineering changes.

Impairment of Long-Lived Assets

Long-lived assets are reviewed for impairment upon the occurrence of events or changes in circumstances that indicate that the carrying value of the assets may not be recoverable, as measured by comparing their net book value to the projected undiscounted future cash flows generated by their use. Impaired assets are recorded at their estimated fair value using a discounted cash flow analysis.

Goodwill and Indefinite-Lived Intangible Assets

In accordance with ASC 350, the Company reviews the carrying value of goodwill and indefinite-lived intangible assets annually on October 31, or upon the occurrence of events or changes in circumstances that indicate that the carrying value of the goodwill or intangible assets may not be recoverable. The Company evaluates the recoverability of these assets based on the estimated fair value of each of the fifteen reporting units and the indefinite-lived intangible asset. See Note 4 for a further discussion on goodwill and intangible assets.

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Borrowing Expenses

Expenses, inclusive of commissions and professional fees, incurred in securing and issuing debt are capitalized and included in Other noncurrent assets. These assets are amortized over the life of the related borrowing and the related amortization is included in Interest expense in the Consolidated Statements of Operations.

Earnings per Common Share

Earnings per common share (“EPS”) is computed by dividing net income by the weighted average number of shares of common stock (basic) plus common stock equivalents and unvested shares (diluted) outstanding during the year. Common stock equivalents consist of stock options and deferred compensation units (“DCUs”) and have been included in the calculation of weighted average shares outstanding using the treasury stock method.

ASC 260 concludes that all outstanding unvested share-based payment awards that contain rights to nonforfeitable dividends participate in undistributed earnings with common shareholders. If awards are considered participating securities, the Company is required to apply the two-class method of computing basic and diluted earnings per share. The Company has determined that its outstanding unvested shares are participating securities. Accordingly, earnings per common share were computed using the two-class method prescribed by ASC 260. Net income attributable to common shareholders was reduced by $0.1 million, $1.2 million and $1.4 million in 2012, 2011 and 2010, respectively.

Basic weighted average shares outstanding reconciles to diluted weighted average shares outstanding as follows:


	2012		2011		2010
	(In thousands)
Basic weighted average common shares outstanding		82,689		82,145		80,466
Dilutive effect of stock options, DCUs and unvested shares		952		1,398		1,517

Diluted weighted average common shares outstanding		83,641		83,543		81,983

Options to purchase approximately 1.2 million, 0.7 million and 0.2 million shares of common stock in 2012, 2011 and 2010, respectively, were not included in the computation of diluted EPS because the effect of their inclusion would have been antidilutive.

Share-Based Compensation

The Company accounts for share-based payments in accordance with ASC 718. Accordingly, the Company expenses the fair value of awards made under its share-based compensation plans. That cost is recognized in the consolidated financial statements over the requisite service period of the grants. See Note 13 for further discussion on share-based compensation.

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Depreciation and Amortization

Property and equipment are stated at cost, with depreciation and amortization provided using the straight-line method over the following estimated useful lives:


Land improvements			8 to 12 years
Buildings and improvements			8 to 30 years
Machinery, equipment and other			3 to 12 years
Office and transportation equipment			3 to 10 years

Certain identifiable intangible assets are amortized over their estimated useful lives using the straight-line method. The estimated useful lives used in the computation of amortization of identifiable intangible assets are as follows:


Patents			5 to 17 years
Trade names			10 to 20 years
Customer relationships			3 to 20 years
Non-compete agreements			2 to 5 years
Unpatented technology and other			4 to 20 years

Research and Development Expenditures

Costs associated with research and development are expensed in the period incurred and are included in Cost of sales within the Consolidated Statements of Operations. Research and development expenses, which include costs associated with developing new products and major improvements to existing products, were $36.4 million, $36.0 million and $31.8 million in 2012, 2011 and 2010, respectively.

Foreign Currency Translation

The functional currency of substantially all operations outside the United States is the respective local currency. Accordingly, those foreign currency balance sheet accounts have been translated using the exchange rates in effect as of the balance sheet date. Income statement amounts have been translated using the average exchange rate for the year. The gains and losses resulting from changes in exchange rates from year to year have been reported in Accumulated other comprehensive loss in the Consolidated Balance Sheets. The effect of transaction gains and losses is reported within Other income (expense)-net in the Consolidated Statements of Operations.

Income Taxes

Income tax expense includes United States, state, local and international income taxes. Deferred tax assets and liabilities are recognized for the tax consequences of temporary differences between the financial reporting and the tax basis of existing assets and liabilities and for loss carryforwards. The tax rate used to determine the deferred tax assets and liabilities is the enacted tax rate for the year and manner in which the differences are expected to reverse. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized.

Concentration of Credit Risk

The Company is not dependent on a single customer, the largest of which accounted for less than 2% of net sales for all years presented.

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Recently Adopted Accounting Pronouncements

In May 2011, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2011-04, “Fair Value Measurement: Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRS” (“ASU 2011-04”), which was issued to provide a consistent definition of fair value and ensure that the fair value measurement and disclosure requirements are similar between GAAP and IFRS. ASU 2011-04 changes certain fair value measurement principles and enhances the disclosure requirements particularly for Level 3 fair value measurements. The Company adopted this guidance on January 1, 2012, and its adoption did not impact the consolidated financial position, results of operations or cash flows of the Company.

In June 2011, FASB issued ASU 2011-05 “Presentation of Comprehensive Income.” ASU 2011-05 allows an entity to present components of net income and other comprehensive income in one continuous statement, referred to as the statement of comprehensive income, or in two separate, but consecutive statements. The new guidance eliminates the current option to report other comprehensive income and its components in the statement of changes in equity. While ASU 2011-05 changes the presentation of comprehensive income, there are no changes to the components that are recognized in net income or other comprehensive income under current accounting guidance. In December 2011, FASB issued ASU 2011-12 “Comprehensive Income (Topic 220); Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05.” ASU 2011-12 deferred certain aspects of ASU 2011-05. The new guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2011. The Company adopted ASU 2011-05 and the deferrals in ASU 2011-12 on January 1, 2012 and the adoption did not impact the consolidated financial position, results of operations or cash flows of the Company.

New Accounting Pronouncements

In July 2012, the FASB issued ASU 2012-02, “Intangibles—Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment” (ASU 2012-02), which allows an entity to first assess qualitative factors to determine whether it is necessary to perform a quantitative impairment test of an indefinite-lived intangible asset. Under ASU 2012-02, an entity would not be required to calculate the fair value of an indefinite-lived intangible asset if the entity determines, based on qualitative assessment, that it is not more likely than not impaired. The revised standard is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012; however, early adoption is permitted. As of December 31, 2012, the Company did not elect to early adopt ASU 2012-02, however it is not expected to have a material impact on the consolidated financial position, results of operations or cash flows of the Company.

2.	Restructuring

During 2012, 2011 and 2010, the Company recorded restructuring costs as a part of the 2011 and 2009 restructuring initiatives that support the implementation of key strategic efforts designed to facilitate long-term sustainable growth through cost reduction actions, primarily consisting of employee reductions and facility rationalization. The costs incurred related to these initiatives are included in Restructuring expenses in the Consolidated Statements of Operations while the related accruals are included in Accrued expenses in the Consolidated Balance Sheets. Severance costs primarily consist of severance benefits through payroll continuation, COBRA subsidies, outplacement services, conditional separation costs and employer tax liabilities, while exit costs primarily consist of asset disposals or impairments, the termination of a defined benefit plan, legal costs and relocation charges.

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

2011 Initiatives

During 2012 and 2011, the Company recorded pre-tax restructuring expenses totaling $32.5 million and $12.3 million, respectively, related to our 2011 restructuring initiative for exit costs and employee severance related to employee reductions across various functional areas as well as facility rationalization. The 2011 restructuring initiatives included severance benefits for 491 employees in 2012 and 292 employees in 2011. The 2011 initiative was completed by the end of 2012 and no further restructuring is currently planned. Severance payments are expected to be fully paid in the next 12 months using cash from operations.

2009 Initiatives

During 2010, the Company recorded $11.1 million of pre-tax restructuring expenses related to our 2009 restructuring initiative for employee severance related to employee reductions across various functional areas as well as facility closures resulting from the Company’s cost savings initiatives. The 2009 restructuring initiative included severance benefits for over 700 employees. The 2009 initiatives were substantially complete by the end of 2010, with restructuring charges totaling $23.2 million for the program.

Pre-tax restructuring expenses by segment, for 2012, were as follows:


	Severance Costs		Exit Costs		Total
	(In thousands)
Fluid & Metering Technologies	$	6,226	$	36	$	6,262
Health & Science Technologies		11,223		3,521		14,744
Fire & Safety/Diversified Products		3,226		5,114		8,340
Corporate/Other		2,844		283		3,127

Total restructuring costs	$	23,519	$	8,954	$	32,473

Pre-tax restructuring expenses by segment, for 2011, were as follows:


	Severance Costs		Exit Costs		Total
	(In thousands)
Fluid & Metering Technologies	$	2,800	$	61	$	2,861
Health & Science Technologies		2,007		123		2,130
Fire & Safety/Diversified Products		4,430		797		5,227
Corporate/Other		2,096		—		2,096

Total restructuring costs	$	11,333	$	981	$	12,314

Pre-tax restructuring expenses by segment, for 2010, were as follows:


	Severance Costs		Exit Costs		Total
	(In thousands)
Fluid & Metering Technologies	$	2,630	$	320	$	2,950
Health & Science Technologies		3,511		1,650		5,161
Fire & Safety/Diversified Products		1,230		—		1,230
Corporate/Other		1,754		—		1,754

Total restructuring costs	$	9,125	$	1,970	$	11,095

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Restructuring accruals of $10.9 million and $5.9 million at December 31, 2012 and 2011, respectively, are reflected in Accrued expenses in our Consolidated Balance Sheets as follows:


	2011 Initiative			2009 Initiative			Total
	(In thousands)
Balance at January 1, 2011	$	—		$	3,543		$	3,543
Restructuring expenses		12,314			—			12,314
Payments, utilization and other		(6,439	)		(3,543	)		(9,982	)

Balance at December 31, 2011		5,875			—			5,875
Restructuring expenses		32,473			—			32,473
Payments, utilization and other		(27,461	)		—			(27,461	)

Balance at December 31, 2012	$	10,887		$	—		$	10,887

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

3.	Balance Sheet Components


	December 31,
	2012		2011
	(In thousands)
RECEIVABLES
Customers	$	257,114	$	254,816
Other		4,577		3,889

Total		261,691		258,705
Less allowance for doubtful accounts		5,596		5,860

Total receivables — net	$	256,095	$	252,845

INVENTORIES
Raw materials and components parts	$	139,229	$	155,577
Work in process		33,025		40,506
Finished goods		62,696		58,175

Total	$	234,950	$	254,258

PROPERTY, PLANT AND EQUIPMENT
Land and improvements	$	31,787	$	30,320
Buildings and improvements		141,952		128,932
Machinery, equipment and other		288,542		278,936
Office and transportation equipment		95,920		98,341
Construction in progress		12,040		8,820

Total		570,241		545,349
Less accumulated depreciation and amortization		351,080		331,632

Total property, plant and equipment — net	$	219,161	$	213,717

ACCRUED EXPENSES
Payroll and related items	$	55,618	$	51,728
Management incentive compensation		15,974		17,402
Income taxes payable		10,284		8,456
Deferred income taxes		—		167
Insurance		8,974		6,495
Warranty		4,875		4,417
Deferred revenue		9,682		7,954
Restructuring		10,887		5,875
Liability for uncertain tax positions		2,679		1,061
Accrued interest		1,713		1,424
Contingent consideration for acquisition		3,528		1,500
Other		25,962		24,217

Total accrued expenses	$	150,176	$	130,696

OTHER NONCURRENT LIABILITIES
Pension and retiree medical obligations	$	96,853	$	91,542
Liability for uncertain tax positions		4,989		5,262
Deferred revenue		6,534		3,198
Contingent consideration for acquisition		5,515		—
Other		14,484		15,844

Total other noncurrent liabilities	$	128,375	$	115,846

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)


	2012			2011			2010
	(In thousands)
VALUATION AND QUALIFYING ACCOUNTS(1)
Beginning balance January 1	$	5,860		$	5,322		$	6,160
Charged to costs and expenses, net of recoveries		653			1,044			945
Utilization		(1,151	)		(917	)		(1,879	)
Currency translation and other		234			411			96

Ending balance December 31	$	5,596		$	5,860		$	5,322

(1)	Includes provision for doubtful accounts, sales returns and sales discounts granted to customers.

4.	Goodwill and Intangible Assets

The changes in the carrying amount of goodwill for 2012 and 2011, by business segment, were as follows:


	Fluid & Metering Technologies			Health & Science Technologies			Fire & Safety/ Diversified Products			Total
Goodwill	$	551,064		$	418,776		$	273,910		$	1,243,750
Accumulated impairment losses		(6,659	)		—			(30,090	)		(36,749	)

Balance at January 1, 2011(1)		544,405			418,776			243,820			1,207,001
Acquisition adjustments		—			434			—			434
Acquisitions (Note 12)		—			231,189			—			231,189
Foreign currency translation		(2,765	)		(1,493	)		(3,000	)		(7,258	)

Balance at December 31, 2011(1)		541,640			648,906			240,820			1,431,366
Acquisition adjustments		—			1,424			—			1,424
Acquisitions (Note 12)		—			50,387			—			50,387
Foreign currency translation		3,406			2,307			3,378			9,091
Goodwill impairment		(20,721	)		(149,820	)		—			(170,541	)

Balance at December 31, 2012	$	524,325		$	553,204		$	244,198		$	1,321,727

(1)	Revised to reflect the movement of the Dispensing Equipment segment to the Fire & Safety/Diversified Products segment and the transfer of $20.6 million of goodwill related to the movement of our Trebor business unit from the Health & Science Technologies segment to the Fluid & Metering Technologies segment.

ASC 350 requires that goodwill be tested for impairment at the reporting unit level on an annual basis and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying value. Goodwill represents the purchase price in excess of the net amount assigned to assets acquired and liabilities assumed.

In prior periods, the Company disclosed certain reporting units for which the estimated fair value did not significantly exceed carrying value. Assumptions used in estimating fair value included successful execution of business forecasts and favorable market conditions. Consistent with the Company’s approach in its annual impairment testing, in assessing the fair value of the reporting units, the Company considered both the market approach and income approach. Under the market approach, the fair value of the reporting unit is based on comparing the reporting unit to comparable publicly traded companies. Under the income approach, the fair value of the reporting unit is based on the present value of estimated future cash flows. The income approach is

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

dependent on a number of significant management assumptions including estimates of operating results, capital expenditures, other operating costs and discount rates. Weighting was equally attributed to both the market and income approaches (50% each) in arriving at the fair value of the reporting units. As a result of our annual impairment test for the IOP reporting unit and as a result of the reorganization of certain FMT reporting units, the Company determined that the fair value of the IOP and WST reporting units was less than the carrying value of the net assets of the reporting units, and thus the Company performed step two of the goodwill impairment test.

In step two of the goodwill impairment test, the Company determined the implied fair value of the goodwill and compared it to the carrying value, which resulted in a $149.8 million goodwill impairment charge at the IOP reporting unit and a $20.7 million goodwill impairment charge at the WST reporting unit.

The following table provides the gross carrying value and accumulated amortization for each major class of intangible asset at December 31, 2012 and 2011:


	At December 31, 2012									At December 31, 2011
	Gross Carrying Amount		Accumulated Amortization			Net		Weighted Average Life		Gross Carrying Amount		Accumulated Amortization			Net
			(In thousands)									(In thousands)
Amortizable intangible assets:
Patents	$	10,650	$	(4,273	)	$	6,377		11	$	11,506	$	(4,315	)	$	7,191
Trade names		103,113		(21,603	)		81,510		16		72,823		(18,205	)		54,618
Customer relationships		230,196		(93,273	)		136,923		10		221,076		(69,280	)		151,796
Non-compete agreements		3,505		(2,827	)		678		3		4,801		(4,053	)		748
Unpatented technology		74,758		(24,211	)		50,547		11		70,741		(15,617	)		55,124
Other		6,841		(3,604	)		3,237		10		6,793		(3,156	)		3,637

Total amortizable intangible assets		429,063		(149,791	)		279,272				387,740		(114,626	)		273,114
Unamortized intangible assets:
Banjo trade name		62,100		—			62,100				62,100		—			62,100
CVI Melles Griot trade name		—		—			—				47,008		—			47,008

Total intangible assets	$	491,163	$	(149,791	)	$	341,372			$	496,848	$	(114,626	)	$	382,222

The unamortized Banjo trade name and the CVI Melles Griot trade names were determined to be indefinite lived intangible assets which are tested for impairment on an annual basis in accordance with ASC 350 or more frequently if events or changes in circumstances indicate that the asset might be impaired. Consistent with the Company’s approach in its annual impairment testing in assessing the fair value of the indefinite lived intangible assets, the Company used the relief-from-royalty method, a form of the income approach. The relief-from-royalty method is dependent of a number of significant management assumptions, including estimates of revenues, royalty rates and discount rates. As a result of our annual impairment test, the Company concluded that the fair value of the CVI Melles Griot trade names within the IOP reporting unit was less than the carrying value, resulting in a $21.0 million impairment charge. The Company also determined that the CVI Melles Griot trade names no longer had an indefinite life and reclassified the remaining $26.0 million to definite lived assets that will be amortized over a remaining useful life of 15 years.

A long-lived asset impairment exists when the carrying amount of the asset exceeds its fair value. Assessments of possible impairments of long-lived assets are made when events or changes in circumstances indicate that the carrying value of the asset may not be recoverable through future operations. The amount and

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

timing of impairment charges for these assets require the estimation of future cash flows and the fair value of the related assets. Due to continued market softness in municipal end markets, the Company concluded that certain long lived assets within the WST reporting unit had a fair value that was less than the carrying value of the assets, resulting in a $7.0 million impairment charge.

Amortization of intangible assets was $41.5 million, $35.5 million and $25.7 million in 2012, 2011 and 2010, respectively. Based on intangible asset balances as of December 31, 2012, amortization expense is expected to approximate $43.7 million in 2013, $41.6 million in 2014, $39.4 million in 2015, $37.5 million in 2016 and $28.4 million in 2017.

5.	Borrowings

Borrowings at December 31, 2012 and 2011 consisted of the following:


	2012		2011
	(In thousands)
Revolving Facility	$	21,000	$	50,798
4.2% Senior Notes, due December 2021		349,197		349,125
4.5% Senior Notes, due December 2020		298,689		298,555
2.58% Senior Euro Notes, due June 2015		107,042		104,655
Other borrowings		10,648		5,677

Total borrowings		786,576		808,810
Less current portion		7,335		2,444

Total long-term borrowings	$	779,241	$	806,366

On June 27, 2011, the Company and certain of its subsidiaries entered into a credit agreement (the “Credit Agreement”), as borrowers (the “Borrowers”), with Bank of America, N.A., as administrative agent, swing line lender and an issuer of letters of credit, and other lenders party thereto which provided for a new revolving credit facility (the “Revolving Facility”). The Revolving Facility replaced the Company’s previous $600.0 million credit facility, which expired in December 2011.

The Revolving Facility is in an aggregate principal amount of $700.0 million with a maturity date of June 27, 2016. The maturity date may be extended under certain conditions for an additional one-year term prior to the second anniversary of the initial closing date of June 27, 2011. Up to $75.0 million of the Revolving Facility is available for the issuance of letters of credit. Additionally, up to $25.0 million of the Revolving Facility is available to the Company for swing line loans, available on a same-day basis.

Proceeds of the Revolving Facility are available for use by the Borrowers for working capital and other general corporate purposes, including refinancing existing debt of the Company and its subsidiaries. The Company may request increases in the lending commitments under the Credit Agreement, but the aggregate lending commitments may not exceed $950.0 million. The Company has the right, subject to certain conditions set forth in the Credit Agreement, to designate certain foreign subsidiaries of the Company as borrowers under the Credit Agreement. In connection with any such designation, the Company is required to guarantee the obligations of any such subsidiaries under the Credit Agreement. Under the Credit Agreement, Fast & Fluid Management Europe B.V., (“FME”) and IDEX UK Ltd. (“IDEX UK”) were approved by the lenders as designated borrowers. At December 31, 2012, FME and IDEX UK had no borrowings under the Revolving Facility.

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Borrowings under the Revolving Facility bear interest, at either an alternate base rate or an adjusted LIBOR rate plus, an applicable margin. Such applicable margin is based on the Company’s senior, unsecured, long-term debt rating and can range from .875% to 1.70%. Based on the Company’s credit rating at December 31, 2012, the applicable margin was 1.05%. Interest is payable (a) in the case of base rate loans, quarterly, and (b) in the case of LIBOR rate loans, on the maturity date of the borrowing, or quarterly from the effective date for borrowings exceeding three months. An annual Revolving Facility fee, also based on the Company’s credit rating, is currently 20 basis points and is payable quarterly.

The Credit Agreement contains affirmative and negative covenants that the Company believes are usual and customary for senior unsecured credit agreements, including a financial covenant requiring the maintenance of a 3.25 to 1.0 or lower leverage ratio, which is the ratio of the Company’s consolidated total debt to its consolidated EBITDA, each as defined in the Credit Agreement.

The Credit Agreement also contains customary events of default (subject to grace periods, as appropriate) including among others: nonpayment of principal, interest or fees; breach of the representations or warranties in any material respect; breach of the financial, affirmative or negative covenants; payment default on, or acceleration of, other material indebtedness; bankruptcy or insolvency; material judgments entered against the Company or any of its subsidiaries; certain specified events under the Employee Retirement Income Security Act of 1974, as amended; certain changes in control of the Company; and the invalidity or unenforceability of the Credit Agreement or other documents associated with the Credit Agreement.

At December 31, 2012, $21.0 million was outstanding under the Revolving Facility, with $6.5 million of outstanding letters of credit, resulting in net available borrowing capacity under the Revolving Facility at December 31, 2012 of approximately $672.5 million.

On June 9, 2010, the Company completed a private placement of €81.0 million ($96.8 million) aggregate principal amount of 2.58% Series 2010 Senior Euro Notes due June 9, 2015 (“2.58% Senior Euro Notes”) pursuant to a Master Note Purchase Agreement, dated June 9, 2010 (the “Purchase Agreement”). The Purchase Agreement provides for the issuance of additional series of notes in the future, provided that the aggregate principal amount outstanding under the agreement at any time does not exceed $750.0 million. The 2.58% Senior Euro Notes bear interest at a rate of 2.58% per annum, which is payable semi-annually in arrears on each June 9th and December 9th and will mature on June 9, 2015. The 2.58% Senior Euro Notes are unsecured obligations of the Company and rank pari passu in right of payment with all of the Company’s other senior debt. The Company may at any time prepay all or any portion of the 2.58% Senior Euro Notes; provided that any such portion is greater than 5% of the aggregate principal amount of Notes then outstanding under the Purchase Agreement. In the event of a prepayment, the Company would be required to pay an amount equal to par plus accrued interest plus a make-whole premium. The Purchase Agreement contains certain covenants that restrict the Company’s ability to, among other things, transfer or sell assets, create liens and engage in certain mergers or consolidations. In addition, the Company must comply with a leverage ratio and interest coverage ratio as set forth in the Purchase Agreement. The Purchase Agreement provides for customary events of default. In the case of an event of default arising from specified events of bankruptcy or insolvency, all outstanding 2.58% Senior Euro Notes will become due and payable immediately without further action or notice. In the case of payment events of defaults, any holder of the 2.58% Senior Euro Notes affected thereby may declare all the 2.58% Senior Euro Notes held by it due and payable immediately. In the case of any other event of default, a majority of the holders of the 2.58% Senior Euro Notes may declare all the 2.58% Senior Euro Notes to be due and payable immediately.

On December 6, 2010, the Company completed a public offering of $300.0 million 4.5% senior notes due December 15, 2020 (“4.5% Senior Notes”). The net proceeds from the offering of $295.7 million, after deducting

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

a $1.6 million issuance discount, a $1.9 million underwriting commission and $0.8 million offering expenses, were used to repay $250.0 million of outstanding bank indebtedness, with the balance used for general corporate purposes. The 4.5% Senior Notes bear interest at a rate of 4.5% per annum, which is payable semi-annually in arrears on each June 15th and December 15th. The Company may redeem all or a portion of the 4.5% Senior Notes at any time prior to maturity at the redemption prices set forth in the Note Indenture governing the 4.5% Senior Notes. The Company may issue additional debt from time to time pursuant to the Indenture. The Indenture and 4.5% Senior Notes contain covenants that limit the Company’s ability to, among other things, incur certain liens securing indebtedness, engage in certain sale-leaseback transactions, and enter into certain consolidations, mergers, conveyances, transfers or leases of all or substantially all the Company’s assets. The terms of the 4.5% Senior Notes also require the Company to make an offer to repurchase the 4.5% Senior Notes upon a change of control triggering event (as defined in the Indenture) at a price equal to 101% of their principal amount plus accrued and unpaid interest, if any.

On December 9, 2011, the Company completed a public offering of $350.0 million 4.2% senior notes due December 15, 2021 (“4.2% Senior Notes”). The net proceeds from the offering of $346.2 million, after deducting a $0.9 million issuance discount, a $2.3 million underwriting commission and $0.6 million offering expenses, were used to repay $306.0 million of outstanding bank indebtedness, with the balance used for general corporate purposes. The 4.2% Senior Notes bear interest at a rate of 4.2% per annum, which is payable semi-annually in arrears on each June 15th and December 15th. The Company may redeem all or a portion of the 4.2% Senior Notes at any time prior to maturity at the redemption prices set forth in the Note Indenture governing the 4.2% Senior Notes. The Company may issue additional debt from time to time pursuant to the Indenture. The Indenture and 4.2% Senior Notes contain covenants that limit the Company’s ability to, among other things, incur certain liens securing indebtedness, engage in certain sale-leaseback transactions, and enter into certain consolidations, mergers, conveyances, transfers or leases of all or substantially all the Company’s assets. The terms of the 4.2% Senior Notes also require the Company to make an offer to repurchase the 4.2% Senior Notes upon a change of control triggering event (as defined in the Indenture) at a price equal to 101% of their principal amount plus accrued and unpaid interest, if any.

Other borrowings of $10.6 million at December 31, 2012 were comprised of capital leases, debt at international locations maintained for working capital purposes and international debt as a result of acquisitions. Interest is payable on the outstanding debt balances at the international locations at rates ranging from 0.4% to 3.7% per annum.

There are two key financial covenants that the Company is required to maintain in connection with the Revolving Facility and 2.58% Senior Euro Notes. The most restrictive financial covenants under these debt instruments require a minimum interest coverage ratio of 3.0 to 1 and a maximum leverage ratio of 3.25 to 1. At December 31, 2012, the Company was in compliance with both of these financial covenants. There are no financial covenants relating to the 4.5% Senior Notes or 4.2% Senior Notes.

Total borrowings at December 31, 2012 have scheduled maturities as follows (in thousands):


2013	$	7,335
2014		946
2015		107,641
2016		21,517
2017		1,151
Thereafter		647,986

Total borrowings	$	786,576

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

6.	Derivative Instruments

The Company enters into cash flow hedges to reduce the exposure to variability in certain expected future cash flows. The type of cash flow hedges the Company enters into includes foreign currency contracts and interest rate exchange agreements that effectively convert a portion of floating-rate debt to fixed-rate debt and are designed to reduce the impact of interest rate changes on future interest expense.

The effective portion of gains or losses on interest rate exchange agreements is reported in accumulated other comprehensive income (loss) in shareholders’ equity and reclassified into net income in the same period or periods in which the hedged transaction affects net income. The remaining gain or loss in excess of the cumulative change in the present value of future cash flows or the hedged item, if any, is recognized into net income during the period of change.

Fair values relating to derivative financial instruments reflect the estimated amounts that the Company would receive or pay to sell or buy the contracts based on quoted market prices of comparable contracts at each balance sheet date.

As of December 31, 2012, the Company did not have any interest rate or foreign exchange contracts outstanding.

On April 15, 2010, the Company entered into a forward starting interest rate contract with a notional amount of $300.0 million with a settlement date in December 2010. This contract was entered into in anticipation of the issuance of the 4.5% Senior Notes and was designed to lock in the market interest rate as of April 15, 2010. In December 2010, the Company settled and paid this interest rate contract for $31.0 million. The $31.0 million is being amortized into interest expense over the 10 year term of the 4.5% Senior Notes, which results in an effective interest rate of 5.8%.

On July 12, 2011, the Company entered into a forward starting interest rate contract with a notional amount of $350.0 million and a settlement date of September 30, 2011. This contract was entered into in anticipation of the issuance of the 4.2% Senior Notes and was designed to lock in the market interest rate as of July 12, 2011. On September 29, 2011, the Company settled this interest rate contract for $34.7 million with a payment made on October 3, 2011. Simultaneously, the Company entered into a separate interest rate contract with a notional amount of $350.0 million and a settlement date of February 28, 2012. The contract was entered into in anticipation of the expected issuance of the 4.2% Senior Notes and was designed to maintain the market rate as of July 12, 2011. In December 2011, the Company settled and paid the September interest rate contract for $4.0 million, resulting in a total settlement of $38.7 million. Of the $38.7 million, $0.8 million was recognized as other expense in 2011 and the balance of $37.9 million is being amortized into interest expense over the 10 year term of the 4.2% Senior Notes, which results in an effective interest rate of 5.3%.

The following table summarizes the gain (loss) recognized and the amounts and location of income (expense) and gain (loss) reclassified into income for interest rate contracts and foreign currency contracts for the year ended December 31, 2012 and 2011:


	Loss Recognized in Other Comprehensive Income					Income (Expense) and Gain (Loss) Reclassified into Income						Income Statement Caption
	Twelve Months Ended December 31,
	2012		2011			2012			2011
	(In thousands)
Interest rate agreements	$	—	$	(38,797	)	$	(7,637	)	$	(6,197	)	Interest expense
Interest rate agreements		—		—			—			(786	)	Other expense
Foreign exchange contracts		—		(55	)		—			227		Sales

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Approximately $7.4 million of the pre-tax amount included in accumulated other comprehensive loss in shareholders’ equity at December 31, 2012 will be recognized to net income over the next 12 months as the underlying hedged transactions are realized.

7.	Fair Value Measurements

ASC 820 “Fair Value Measurements and Disclosures” defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The standard utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

	•		Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.

	•		Level 2: Inputs, other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

	•		Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.

The following table summarizes the basis used to measure the Company’s financial assets (liabilities) at fair value on a recurring basis in the balance sheet at December 31, 2012 and 2011:


	Basis of Fair Value Measurements
	Balance at December 31, 2012			Level 1		Level 2		Level 3
	(In thousands)
Money market investments	$	11,165		$	11,165		—		—
Available for sale securities		2,862			2,862		—		—
Contingent consideration		(9,043	)		—		—		(9,043	)


	Balance at December 31, 2011			Level 1		Level 2		Level 3
	(In thousands)
Money market investments	$	11,899		$	11,899		—		—
Available for sale securities		2,785			2,785		—		—
Contingent consideration		(3,000	)		—		—	$	(3,000	)

There were no transfers of assets or liabilities between Level 1 and Level 2 in 2012 or 2011.

In determining the fair value of the contingent consideration potentially due on the acquisition of Matcon, the Company used probability weighted estimates adjusted for the time value of money. The Matcon contingent consideration liability is valued at $9.0 million, of which $8.4 million was recorded as part of the purchase price as of the opening balance sheet date and the remaining $0.6 was recognized to SG&A in the fourth quarter of 2012. At December 31, 2012, $3.5 million of the contingent consideration is included in Accrued expenses and $5.5 million of contingent consideration is recorded in Noncurrent liabilities in the Consolidated Balance Sheet. In February 2012, the Company paid $1.5 million as contingent consideration for the AT Films acquisition. The remaining liability on the AT Films contingent consideration of $1.5 million was recognized as a benefit to SG&A in 2012, as the Company determined that the contingent consideration will not be earned.

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The carrying value of our cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximates their fair values because of the short term nature of these instruments. At December 31, 2012, the fair value of our Revolving Facility, 2.58% Senior Euro Notes, 4.5% Senior Notes and 4.2% Senior Notes, based on quoted market prices and current market rates for debt with similar credit risk and maturity, was approximately $806.3 million compared to the carrying value of $775.9 million. This fair value measurement is classified as Level 2 within the fair value hierarchy since it is determined based upon significant inputs observable in the market, including interest rates on recent financing transactions to entities with a credit rating similar to ours.

8.	Commitments and Contingencies

The Company leases certain office facilities, warehouses and data processing equipment under operating leases. Rental expense totaled $18.4 million, $19.0 million and $13.9 million in 2012, 2011, and 2010, respectively.

The aggregate future minimum lease payments for operating and capital leases as of December 31, 2012 were as follows:


	Operating		Capital
	(In thousands)
2013	$	14,078	$	578
2014		8,543		562
2015		6,048		561
2016		3,221		560
2017		2,347		1,155
2018 and thereafter		7,114		100

Warranty costs are provided for at time of sale. The warranty provision is based on historical costs and adjusted for specific known claims. A rollforward of the warranty reserve is as follows:


	2012			2011			2010
	(In thousands)
Beginning balance January 1	$	4,417		$	3,831		$	4,383
Provision for warranties		5,398			4,648			4,331
Claim settlements		(5,214	)		(4,443	)		(4,665	)
Other adjustments, including acquisitions and currency translation		274			381			(218	)

Ending balance December 31	$	4,875		$	4,417		$	3,831

The Company is party to various legal proceedings arising in the ordinary course of business, none of which is expected to have a material effect on its business, financial condition, results of operations or cash flow.

9.	Common and Preferred Stock

On October 22, 2012, the Company’s Board of Directors approved an increase in the authorized level for repurchases of common stock by $200.0 million. Repurchases under the program was funded with future cash flow generation. During 2012, the Company purchased a total of 2.2 million shares at a cost of $89.6 million. No shares were purchased in 2011.

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

At December 31, 2012 and 2011, the Company had 150 million shares of authorized common stock, with a par value of $.01 per share and 5 million shares of authorized preferred stock with a par value of $.01 per share. No preferred stock was issued as of December 31, 2012 and 2011.

10.	Income Taxes

Pretax income for 2012, 2011 and 2010 was taxed in the following jurisdictions:


	2012		2011		2010
	(In thousands)
Domestic	$	65,738	$	192,857	$	161,573
Foreign		20,466		81,024		70,301

Total	$	86,204	$	273,881	$	231,874

The provision (benefit) for income taxes for 2012, 2011, and 2010, was as follows:


	2012			2011			2010
	(In thousands)
Current
U.S.	$	59,811		$	48,823		$	59,384
State and local		5,764			3,434			4,548
Foreign		20,228			31,343			18,178

Total current		85,803			83,600			82,110
Deferred
U.S.		(31,246	)		4,792			(6,550	)
State and local		(2,377	)		(1,103	)		(293	)
Foreign		(3,606	)		(7,265	)		(493	)

Total deferred		(37,229	)		(3,576	)		(7,336	)

Total provision for income taxes	$	48,574		$	80,024		$	74,774

Deferred tax assets (liabilities) at December 31, 2012 and 2011 were:


	2012			2011
	(In thousands)
Employee and retiree benefit plans	$	38,401		$	38,626
Depreciation and amortization		(170,630	)		(213,002	)
Inventories		10,851			10,274
Allowances and accruals		7,629			14,103
Interest rate exchange agreement		20,856			23,714
Other		7,059			10,033

Total	$	(85,834	)	$	(116,252	)

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The deferred tax assets and liabilities recognized in the Company’s Consolidated Balance Sheets as of December 31, 2012 and 2011 were:


	2012			2011
	(In thousands)
Deferred tax asset — other current assets	$	32,293		$	26,037
Deferred tax asset — other noncurrent assets		3,222			360

Total deferred tax assets		35,515			26,397
Deferred tax liability — accrued expenses		—			(167	)
Noncurrent deferred tax liability — deferred income taxes		(121,349	)		(142,482	)

Total deferred tax liabilities		(121,349	)		(142,649	)

Net deferred tax liabilities	$	(85,834	)	$	(116,252	)

The provision for income taxes differs from the amount computed by applying the statutory federal income tax rate to pretax income. The computed amount and the differences for 2012, 2011, and 2010 are shown in the following table:


	2012			2011			2010
	(In thousands)
Pretax income	$	86,204		$	273,881		$	231,874

Provision for income taxes:
Computed amount at statutory rate of 35%	$	30,171		$	95,858		$	81,156
State and local income tax (net of federal tax benefit)		2,406			1,515			2,766
Taxes on non-U.S. earnings-net of foreign tax credits		1,189			(4,522	)		(8,545	)
Effect of flow-through entities		(7,846	)		(6,922	)		(516	)
Asset impairments		28,524			—			—
U.S. business tax credits		—			(917	)		(935	)
Domestic activities production deduction		(5,267	)		(4,589	)		(4,720	)
Other		(603	)		(399	)		5,568

Total provision for income taxes	$	48,574		$	80,024		$	74,774

The Company has not provided an estimate for any U.S. or additional foreign taxes on undistributed earnings of foreign subsidiaries that might be payable if these earnings were repatriated since the Company considers these amounts to be permanently invested.

A reconciliation of the beginning and ending amount of unrecognized tax benefits for 2012, 2011 and 2010 are shown in the following table:


	2012			2011			2010
	(In thousands)
Beginning balance January 1	$	5,548		$	6,440		$	5,285
Gross increases for tax positions of prior years		3,017			1,828			3,049
Gross decreases for tax positions of prior years		(98	)		(1,595	)		(675	)
Settlements		—			(338	)		(517	)
Lapse of statute of limitations		(1,961	)		(787	)		(702	)

Ending balance December 31	$	6,506		$	5,548		$	6,440

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

We recognize interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2012, 2011 and 2010, we had approximately $0.7 million, $0.5 million and $0.8 million, respectively, of accrued interest related to uncertain tax positions. As of December 31, 2012, 2011 and 2010, we had approximately $0.5 million, $0.2 million and $0.4 million, respectively, of accrued penalties related to uncertain tax positions.

The total amount of unrecognized tax benefits that would affect our effective tax rate if recognized is $5.8 million, $5.0 million and $5.8 million as of December 31, 2012, 2011 and 2010, respectively. The tax years 2007-2011 remain open to examination by major taxing jurisdictions. Due to the potential for resolution of federal, state and foreign examinations, and the expiration of various statutes of limitation, it is reasonably possible that the Company’s gross unrecognized tax benefits balance may change within the next 12 months by a range of zero to $2.7 million.

The Company had net operating loss and credit carry forwards for U.S. federal purposes at December 31, 2012 and 2011 of $13.9 and $14.0 million, respectively. For non-U.S. purposes, the Company had net operating loss carry forwards at December 31, 2012 and 2011 of $7.8 and $12.4 million, respectively. The federal net operating loss carry forwards are available for use against the Company’s consolidated federal taxable income and expire between 2018 and 2031. The entire balance of the non-U.S. net operating losses are available to be carried forward, with $3.7 million of these losses beginning to expire during the years 2018 through 2021. The remaining $4.1 million of such losses can be carried forward indefinitely.

At December 31, 2012 and 2011, the Company had a foreign capital loss carry forward of approximately $1.0 million and $1.1 million, respectively. The foreign capital loss can be carried forward indefinitely. At both December 31, 2012 and 2011, the Company has a valuation allowance against the deferred tax asset attributable to the foreign capital loss of $0.2 million. At December 31, 2012 and 2011, the Company had state net operating loss and credit carry forwards of approximately $38.8 million and $18.0 million, respectively. If unutilized, the state net operating loss will expire between 2019 and 2032. At December 31, 2012 and 2011, the Company recorded a valuation allowance against the deferred tax asset attributable to the state net operating loss of $1.5 million and $0.3 million, respectively.

11.	Business Segments and Geographic Information

IDEX has three reportable business segments: Fluid & Metering Technologies, Health & Science Technologies and Fire & Safety/Diversified Products. Reporting units in the Fluid & Metering Technologies segment consist of: Banjo; Energy; CFP; DDPT and WST. Reporting units in the Health & Science Technologies segment consist of: IH&S; IOP; Containment; Gast; Micropump and MPT. Reporting units in the Fire & Safety/Diversified Products segment consist of: Fire Suppression; Rescue; Band-It; and Dispensing Equipment.

The Fluid & Metering Technologies segment designs, produces and distributes positive displacement pumps, flow meters, injectors, and other fluid-handling pump modules and systems and provides flow monitoring and other services for the water and wastewater industries. The Health & Science Technologies segment designs, produces and distributes a wide range of precision fluidics, rotary lobe pumps, centrifugal and positive displacement pumps, roll compaction and drying systems used in beverage, food processing, pharmaceutical and cosmetics, pneumatic components and sealing solutions, including very high precision, low-flow rate pumping solutions required in analytical instrumentation, clinical diagnostics and drug discovery, high performance molded and extruded, biocompatible medical devices and implantables, air compressors used in medical, dental and industrial applications, optical components and coatings for applications in the fields of scientific research, defense, biotechnology, aerospace, telecommunications and electronics manufacturing, laboratory and commercial equipment used in the production of micro and nano scale materials, precision

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

photonic solutions used in life sciences, research and defense markets, and precision gear and peristaltic pump technologies that meet exacting original equipment manufacturer specifications. The Fire & Safety/Diversified Products segment produces firefighting pumps and controls, rescue tools, lifting bags and other components and systems for the fire and rescue industry, engineered stainless steel banding and clamping devices used in a variety of industrial and commercial applications, and precision equipment for dispensing, metering and mixing colorants and paints used in a variety of retail and commercial businesses around the world.

Information on the Company’s business segments is presented below, based on the nature of products and services offered. The Company evaluates performance based on several factors, of which operating income is the primary financial measure. Intersegment sales are accounted for at fair value as if the sales were to third parties. Certain prior year amounts have been revised to include the Dispensing Equipment segment as part of the Fire & Safety/Diversified Products segment and to reflect the movement of our Trebor business unit from the Health & Science Technologies segment to the Fluid & Metering Technologies segment.


	2012			2011			2010
	(In thousands)
NET SALES
Fluid & Metering Technologies:
External customers	$	829,320		$	830,821		$	717,579
Intersegment sales		3,968			466			712

Total segment sales		833,288			831,287			718,291
Health & Science Technologies:
External customers		689,574			606,247			405,135
Intersegment sales		5,661			1,653			3,717

Total segment sales		695,235			607,900			408,852
Fire & Safety/Diversified Products:
External customers		435,364			401,383			390,359
Intersegment sales		1,689			1,042			462

Total segment sales		437,053			402,425			390,821
Intersegment eliminations		(11,318	)		(3,161	)		(4,891	)

Total net sales	$	1,954,258		$	1,838,451		$	1,513,073

OPERATING INCOME(1)
Fluid & Metering Technologies(2)	$	146,650		$	164,818		$	131,018
Health & Science Technologies(2)		(62,835	)		106,037			83,258
Fire & Safety/Diversified Products		96,120			85,901			82,334
Corporate office and other(3)		(51,717	)		(52,100	)		(47,494	)

Total operating income		128,218			304,656			249,116
Interest expense		42,250			29,332			16,150
Other income (expense)-net		236			(1,443	)		(1,092	)

Income before taxes	$	86,204		$	273,881		$	231,874

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)


	2012		2011		2010
	(In thousands)
ASSETS
Fluid & Metering Technologies	$	1,023,143	$	1,072,023	$	1,065,953
Health & Science Technologies		1,102,868		1,178,653		693,532
Fire & Safety/Diversified Products		488,886		442,400		484,107
Corporate office and other(3)		170,493		143,031		138,103

Total assets	$	2,785,390	$	2,836,107	$	2,381,695

DEPRECIATION AND AMORTIZATION(4)
Fluid & Metering Technologies	$	29,637	$	32,368	$	31,893
Health & Science Technologies		39,981		30,055		17,253
Fire & Safety/Diversified Products		7,107		8,516		8,638
Corporate office and other		1,587		1,447		324

Total depreciation and amortization	$	78,312	$	72,386	$	58,108

CAPITAL EXPENDITURES
Fluid & Metering Technologies	$	13,535	$	12,543	$	17,314
Health & Science Technologies		13,140		12,938		7,510
Fire & Safety/Diversified Products		6,654		5,644		4,642
Corporate office and other		2,191		3,423		3,303

Total capital expenditures	$	35,520	$	34,548	$	32,769

(1)	Segment operating income excludes net unallocated corporate operating expenses.

(2)	Segment operating income includes asset impairment charge in 2012 for $27.7 million within the Fluid & Metering Technologies segment and $170.8 within the Health & Science Technologies segment.

(3)	Includes intersegment eliminations.

(4)	Excludes amortization of debt issuance expenses.

Information about the Company’s operations in different geographical regions for the years ended December 31, 2012, 2011 and 2010 is shown below. Net sales were attributed to geographic areas based on location of the customer, and no country outside the U.S. was greater than 10% of total revenues.


	2012		2011		2010
	(In thousands)
NET SALES
U.S.	$	963,137	$	857,990	$	766,067
Europe		479,744		492,125		402,056
Other countries		511,377		488,336		344,950

Total net sales	$	1,954,258	$	1,838,451	$	1,513,073

LONG-LIVED ASSETS — PROPERTY, PLANT AND EQUIPMENT
U.S.	$	127,425	$	124,102	$	108,951
Europe		64,137		63,433		68,756
Other countries		27,599		26,182		10,855

Total long-lived assets — net	$	219,161	$	213,717	$	188,562

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

12.	Acquisitions

All of the Company’s acquisitions have been accounted for under ASC 805, Business Combinations. Accordingly, the accounts of the acquired companies, after adjustments to reflect fair values assigned to assets and liabilities, have been included in the consolidated financial statements from their respective dates of acquisition.

2012 Acquisitions

On April 11, 2012, the Company acquired the stock of PPC. PPC specializes in optical components and coatings for applications in the fields of scientific research, aerospace, telecommunications and electronics manufacturing. Located in Boulder, Colorado, PPC has annual revenues of approximately $7.0 million. PPC operates within the Health & Science Technologies segment as a part of the IOP platform. The Company acquired PPC for an aggregate purchase price of $20.6 million in cash, which was funded from operations. Goodwill and intangible assets recognized as part of this transaction were $13.9 million and $5.1 million, respectively. The $13.9 million of goodwill is not deductible for tax purposes.

On April 30, 2012, the Company acquired the stock of ERC. ERC is a leader in the manufacture of gas liquid separations and detection solutions for the life science, analytical instrumentation and clinical chemistry markets. ERC’s pioneering products include in-line membrane vacuum degassing solutions, refractive index detectors and ozone generation systems. ERC’s original equipment degassing solutions are considered the “standard” for many of the world’s leading instrument producers. Located in Kawaguchi, Japan, ERC has annual revenues of approximately $27.0 million (¥2.14 billion) and operates as part of the IH&S platform within the Health & Science Technologies segment. The Company acquired ERC for an aggregate purchase price of $18.0 million (¥1.47 billion), consisting of $13.3 million in cash and assumption of approximately $4.7 million of debt. The cash payment was financed with borrowings under the Company’s Revolving Facility. Goodwill and intangible assets recognized as part of this transaction were $8.5 million and $5.6 million, respectively. The $8.5 million of goodwill is not deductible for tax purposes.

On July 20, 2012, the Company acquired the stock of Matcon. Matcon is a global leader in material processing solutions for high value powders used in the manufacture of pharmaceuticals, food, plastics, and fine chemicals. Matcon’s innovative products include the original cone valve powder discharge system and filling, mixing and packaging systems, all of which support their customers’ automation and process requirements. Matcon’s products are critical to their customers’ need to maintain clean, reliable and repeatable formulations of prepackaged foods and pharmaceuticals while helping them achieve lean and agile manufacturing. Located in Evesham, Worcestershire, England, Matcon has annual revenues of approximately $34.4 million (£22.0 million) and operates within the Health & Science Technologies segment in the MPT platform. The Company acquired Matcon for an aggregate purchase price of $45.8 million (£29.1 million), consisting of $35.0 million in cash, $2.4 million of working capital adjustments to be paid in the first quarter of 2013, and contingent consideration valued at $8.4 million as of the opening balance sheet date. The contingent consideration amount is based on 2012 and 2013 earnings before interest, income taxes, depreciation and amortization for Matcon and will be settled in 2013 and 2014, respectively. Based on potential outcomes, the undiscounted amount of all future payments that the Company could be required to pay under the contingent consideration arrangement is estimated between $0 and $15.0 million. Approximately $15.0 million of the purchase price cash payment was financed with borrowings under the Revolving Facility. Goodwill and intangible assets recognized as part of this transaction were $28.0 million and $14.1 million, respectively. The $28.0 million of goodwill is not deductible for tax purposes.

The purchase price for PPC, ERC and Matcon were allocated to the assets acquired and liabilities assumed based on estimated fair values at the date of the acquisition. The Company is in the process of obtaining or finalizing appraisals of tangible and intangible assets and it is continuing to evaluate the initial purchase price

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

allocations, as of the acquisition date, which will be adjusted as additional information relative to the fair values of the assets and liabilities of the businesses become known. Accordingly, management has used its best estimate in the initial purchase price allocation as of the date of these financial statements.

The allocation of the acquisition costs to the assets acquired and liabilities assumed, based on their estimated fair values, is as follows:


(In thousands)	ERC			PPC			Matcon			Total
Accounts receivable	$	5,766		$	877		$	7,768		$	14,411
Inventory		4,224			932			604			5,760
Other current assets, net of cash acquired		981			252			1,880			3,113
Property, plant and equipment		2,738			1,936			5,695			10,369
Goodwill		8,499			13,941			27,947			50,387
Intangible assets		5,642			5,104			14,081			24,827
Other assets		1,509			13			53			1,575

Total assets acquired		29,359			23,055			58,028			110,442
Total liabilities assumed		(16,074	)		(2,465	)		(12,215	)		(30,754	)

Net assets acquired	$	13,285		$	20,590		$	45,813		$	79,688

Acquired intangible assets consist of trade names, non-compete agreements, customer relationships and unpatented technology. The goodwill recorded for the acquisitions reflects the strategic fit and revenue and earnings growth potential of these businesses.

The acquired intangible assets and weighted average amortization periods are as follows:


(In thousands)	Total		Weighted Average Life
Trade names	$	8,973		15
Non-compete agreements		470		3
Customer relationships		11,343		6
Unpatented technology		4,041		8

2012 acquired intangible assets	$	24,827

The Company incurred $2.7 million of acquisition-related transaction costs in 2012. These costs were recorded in selling, general and administrative expense and were related to completed transactions, pending transactions and potential transactions, including certain transactions that ultimately were not completed. During 2012, the Company recorded $0.9 million of fair value inventory charges associated with these acquisitions, which were recorded in cost of sales.

2011 Acquisitions

On January 31, 2011, the Company acquired the membership interests of AT Films. AT Films specializes in optical components and coatings for applications in the fields of scientific research, defense, aerospace, telecommunications and electronics manufacturing. AT Films’ core competence is the design and manufacture of filters, splitters, reflectors and mirrors with the precise physical properties required to support their customers’ most challenging and cutting-edge optical applications. Headquartered in Boulder, Colorado, AT Films operates

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

within the Health & Science Technologies segment as a part of the IOP platform. The Company acquired AT Films for an aggregate purchase price of $34.5 million, consisting of $31.8 million in cash and contingent consideration valued at approximately $2.7 million as of the opening balance sheet date. Goodwill and intangible assets recognized as part of this transaction were $18.2 million and $11.4 million, respectively. The $18.2 million of goodwill is deductible for tax purposes.

On March 11, 2011, the Company completed the acquisition of Microfluidics. Microfluidics is a global leader in the design and manufacture of laboratory and commercial equipment used in the production of micro and nano scale materials for the pharmaceutical and chemical markets. Microfluidics is the exclusive producer of the Microfluidizer® family of high shear fluid processors for uniform particle size reduction, robust cell disruption and nanoparticle creation. Microfluidics operates within the Health & Science Technologies segment as a part of the MPT platform. The Company acquired Microfluidics for an aggregate purchase price of $18.5 million in cash. Goodwill and intangible assets recognized as part of this transaction were $5.9 million and $9.7 million, respectively. The $5.9 million of goodwill is not deductible for tax purposes.

On June 10, 2011, the Company completed the acquisition of CVI Melles Griot (“CVI MG”). CVI MG is a global leader in the design and manufacture of precision photonic solutions used in the life sciences, research, semiconductor, security and defense markets. CVI MG’s innovative products are focused on the generation, control and productive use of light for a variety of key science and industrial applications. Products include specialty lasers and light sources, electro-optical components, specialty shutters and components. In addition, CVI MG produces critical components for life science research, electronics manufacturing, military and other industrial applications including lenses, mirrors, filters and polarizers. These components are utilized in a number of important applications such as spectroscopy, cytometry (cell counting), guidance systems for target designation, remote sensing, menology and optical lithography. CVI MG operates within the Health and Science Technologies segment as part of the IOP platform. The Company acquired CVI MG for an aggregate purchase price of $394.7 million, consisting of $393.3 million in cash and the assumption of approximately $1.4 million of debt. Approximately $365.0 million of the cash payment was financed with borrowings under the Revolving Facility. CVI MG is headquartered in Albuquerque, New Mexico, with manufacturing sites located on three continents. Goodwill and intangible assets recognized as part of this transaction were $208.5 million and $115.8 million, respectively. Approximately $117.7 million of goodwill is deductible for tax purposes.

The purchase price for CVI MG, AT Films and Microfluidics was allocated to the assets acquired and liabilities assumed based on estimated fair values at the date of the acquisition.

The allocation of the acquisition costs to the assets acquired and liabilities assumed, based on their estimated fair values, is as follows:


	AT Films			Microfluidics			CVI MG			Total
	(In thousands)
Accounts receivable	$	947		$	1,760		$	23,978		$	26,685
Inventory		852			2,226			52,868			55,946
Other current assets, net of cash acquired		73			816			7,562			8,451
Property, plant and equipment		5,019			567			31,049			36,635
Goodwill		18,220			5,853			208,540			232,613
Intangible assets		11,435			9,717			115,777			136,929
Other assets		2,731			548			2,112			5,391

Total assets acquired		39,277			21,487			441,886			502,650
Total liabilities assumed		(4,766	)		(2,951	)		(48,572	)		(56,289	)

Net assets acquired	$	34,511		$	18,536		$	393,314		$	446,361

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Of the $136.9 million of acquired intangible assets, $47.0 million was assigned to the CVI Melles Griot trade name and was originally not subject to amortization, however, effective October 31, 2012, the Company began to amortize this asset over 15 years. The remaining $89.9 million of acquired intangible assets consist of patents, trade names, customer relationships, non-compete and unpatented technology. The goodwill recorded for the acquisitions reflects the strategic fit and revenue and earnings growth potential of these businesses.

The acquired intangible assets and weighted average amortization periods are as follows:


	Total		Weighted Average Life
Patents	$	3,017		10
Trade names		4,168		15
Customer relationships		53,895		7
Non-compete agreements		793		2
Unpatented technology		28,048		6

2011 acquired intangible assets	$	89,921

The Company incurred $5.8 million of acquisition-related transaction costs in 2011. These costs were recorded in selling, general and administrative expense and were related to completed transactions, pending transactions and potential transactions, including certain transactions that ultimately were not completed.

2010 Acquisitions

On April 15, 2010, the Company acquired the stock of PPE, previously referred to as Seals, Ltd, a leading provider of proprietary high performance seals and advanced sealing solutions for a diverse range of global industries, including analytical instrumentation, semiconductor/solar and process technologies. PPE consists of the Polymer Engineering and Perlast divisions. PPE’s Polymer Engineering division focuses on sealing solutions for hazardous duty applications. The Perlast division produces highly engineered seals for analytical instrumentation, pharmaceutical, electronics, and food applications. Headquartered in Blackburn, England, PPE operates as part of the Containment group within the Health & Science Technologies Segment. The Company acquired PPE for an aggregate purchase price of $54.0 million, consisting of $51.3 million in cash and the assumption of approximately $2.7 million of debt related items. The cash payment was financed with borrowings under the Company’s credit facility. Goodwill and intangible assets recognized as part of this transaction were $29.7 million and $17.2 million, respectively. The $29.7 million of goodwill is not deductible for tax purposes.

On July 21, 2010, the Company acquired the stock of OBL, S.r.l. (“OBL”), a leading provider of mechanical and hydraulic diaphragm pumps. OBL provides polymer blending systems and related accessories for a diverse range of global industries, including water, waste water, oil and gas, petro-chemical and power generation markets. Headquartered in Milan, Italy, OBL operates within IDEX’s Fluid & Metering Technologies segment as part of the DDPT platform. The Company acquired OBL for cash consideration of $15.4 million. Goodwill and intangible assets recognized as part of this transaction were $7.7 million and $4.0 million, respectively. The $7.7 million of goodwill is not deductible for tax purposes.

On September 17, 2010, the Company acquired the assets of Periflo, a leading provider of peristaltic pumps for the industrial and municipal water & waste water markets. Periflo offers a complete family of peristaltic hose pumps for a wide variety of applications. Periflo operates within IDEX’s Fluid & Metering Technologies segment as part of the DDPT platform. The Company acquired Periflo for cash consideration of $4.3 million. Goodwill and intangible assets recognized as part of this transaction were $2.5 million and $0.7 million, respectively. The $2.5 million of goodwill is deductible for tax purposes.

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

On November 1, 2010, the Company acquired the stock of Fitzpatrick, a global leader in the design and manufacture of process technologies for the pharmaceutical, food and personal care markets. Fitzpatrick designs and manufactures customized size reduction, roll compaction and drying systems to support their customers’ product development and manufacturing processes. Headquartered in Elmhurst, Illinois, Fitzpatrick operates in the MPT platform within the Health & Science Technologies segment. The Company acquired Fitzpatrick for cash consideration of approximately $20.3 million. Goodwill and intangible assets recognized as part of this transaction were $6.0 million and $8.0 million, respectively. The $6.0 million of goodwill is not deductible for tax purposes.

The allocation of the acquisition costs to the assets acquired and liabilities assumed, based on their estimated fair values were as follows:


	2010
	(In thousands)
Current assets, net of cash acquired	$	24,679
Property, plant and equipment		18,344
Goodwill		45,915
Intangible assets		29,861
Other assets		2,906

Total assets acquired		121,705
Total liabilities assumed		(30,439	)

Net assets acquired	$	91,266

Acquired intangible assets consist of trademarks, customer relationships, unpatented technology and non-compete agreements, which are being amortized over a life of 2-15 years. The goodwill recorded for the acquisitions reflects the strategic fit and revenue and earnings growth potential of these businesses.

The acquired intangible assets and weighted average amortization periods are as follows:


	Total		Weighted Average Life
Trade names	$	6,802		13
Customer relationships		14,832		8
Unpatented technology		7,951		14
Non-compete agreements		276		3

2010 acquired intangible assets	$	29,861

The Company incurred $4.0 million of acquisition related transaction costs in 2010, relating to completed, pending and potential transactions that ultimately were not completed.

13.	Share-Based Compensation

The Company maintains two share-based compensation plans for executives, non-employee directors, and certain key employees that authorize the granting of stock options, unvested shares, unvested share units, and other types of awards consistent with the purpose of the plans. The number of shares authorized for issuance under the Company’s plans as of December 31, 2012 totals 10.6 million, of which 3.4 million shares were available for future issuance. Stock options granted under these plans are generally non-qualified, and are granted

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

with an exercise price equal to the market price of the Company’s stock at the date of grant. The majority of the options issued to employees become exercisable in four equal installments, beginning one year from the date of grant, and generally expire 10 years from the date of grant. Stock options granted to non-employee directors cliff vest after one year. Unvested share and unvested share unit awards generally cliff vest after three years for employees and non-employee directors. The Company issued 230,975, 341,876 and 264,915 of unvested shares as compensation to key employees in 2012, 2011 and 2010, respectively.

All unvested shares carry dividend and voting rights, and the sale of the shares is restricted prior to the date of vesting.

The Company accounts for share-based payments in accordance with ASC 718. Accordingly, the Company expenses the fair value of awards made under its share-based plans. That cost is recognized in the consolidated financial statements over the requisite service period of the grants.

Weighted average option fair values and assumptions for the period specified are disclosed in the following table:


	Years Ended December 31,
	2012	2011	2010
Weighted average fair value of grants	$11.40	$12.30	$ 9.56
Dividend yield	1.59%	1.46%	1.51%
Volatility	32.00%	32.72%	33.43%
Risk-free interest rate	0.17% - 3.96%	0.28% - 5.61%	0.32% - 5.67%
Expected life (in years)	5.98	6.14	5.98

The assumptions are as follows:

	•		The Company estimated volatility using its historical share price performance over the contractual term of the option.

	•		The Company uses historical data to estimate the expected life of the option. The expected life assumption for the years ended December 31, 2012, 2011 and 2010 is an output of the Binomial lattice option-pricing model, which incorporates vesting provisions, rate of voluntary exercise and rate of post-vesting termination over the contractual life of the option to define expected employee behavior.

	•		The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods within the contractual life of the option. For the years ended December 31, 2012, 2011 and 2010, we present the range of risk-free one-year forward rates, derived from the U.S. treasury yield curve, utilized in the Binomial lattice option-pricing model.

	•		The expected dividend yield is based on the Company’s current dividend yield as the best estimate of projected dividend yield for periods within the contractual life of the option.

The Company’s policy is to recognize compensation cost on a straight-line basis over the requisite service period for the entire award. Additionally, the Company’s general policy is to issue new shares of common stock to satisfy stock option exercises or grants of unvested shares.

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Total compensation cost for stock options is as follows:


	Years Ended December 31,
	2012			2011			2010
	(In thousands)
Cost of goods sold	$	650		$	805		$	804
Selling, general and administrative expenses		5,642			6,153			6,923

Total expense before income taxes		6,292			6,958			7,727
Income tax benefit		(1,988	)		(2,208	)		(2,450	)

Total expense after income taxes	$	4,304		$	4,750		$	5,277

Total compensation cost for unvested shares is as follows:


	Years Ended December 31,
	2012			2011(1)			2010
	(In thousands)
Cost of goods sold	$	991		$	684		$	311
Selling, general and administrative expenses		5,819			4,434			8,382
Restructuring expenses		—			—			938

Total expense before income taxes		6,810			5,118			9,631
Income tax benefit		(1,682	)		(1,827	)		(2,097	)

Total expense after income taxes	$	5,128		$	3,291		$	7,534

(1)	Reflects the forfeiture of unvested shares related to the Company’s transition to a new CEO in August 2011.

Recognition of compensation cost was consistent with recognition of cash compensation for the same employees. Compensation cost capitalized as part of inventory was immaterial.

As of December 31, 2012, there was $8.3 million and $9.4 million of total unrecognized compensation cost related to stock options and unvested shares, respectively, that is expected to be recognized over a weighted-average period of 1.4 years and 1.0 years, respectively.

A summary of the Company’s stock option activity as of December 31, 2012, and changes during the year ended December 31, 2012 is presented in the following table:


Stock Options	Shares			Weighted Average Price		Weighted-Average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding at January 1, 2012		4,314,044		$	29.61		7.01	$	34,899,200
Granted		764,700			42.66
Exercised		(1,631,923	)		27.77
Forfeited/Expired		(223,079	)		36.60

Outstanding at December 31, 2012		3,223,742		$	33.16		6.37	$	43,106,153

Vested and expected to vest at December 31, 2012		3,100,929		$	32.86		6.28	$	42,398,877
Exercisable at December 31, 2012		1,780,761		$	29.00		4.82	$	31,219,847

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The intrinsic value for stock options outstanding and exercisable is defined as the difference between the market value of the Company’s common stock as of the end of the period, and the grant price. The total intrinsic value of options exercised in 2012, 2011 and 2010, was $23.5 million, $21.9 million and $14.4 million, respectively. In 2012, 2011 and 2010, cash received from options exercised was $45.8 million, $33.1 million and $18.1 million, respectively, while the actual tax benefit realized for the tax deductions from stock options exercised totaled $8.6 million, $8.0 million and $5.2 million, respectively.

A summary of the Company’s unvested share activity as of December 31, 2012, and changes during the year ending December 31, 2012 is presented in the following table:


Unvested Shares	Shares			Weighted-Average Grant Date Fair Value
Nonvested at January 1, 2012		613,375		$	32.44
Granted		230,975			43.56
Vested		(166,134	)		22.00
Forfeited		(88,230	)		38.61

Nonvested at December 31, 2012		589,986		$	40.27

Unvested share grants accrue dividends and their fair value is equal to the market price of the Company’s stock at the date of the grant.

As of 2011, the Company also maintains a share based compensation plan for non-executives. Total expense related to this plan was $2.3 million and $0.8 million in 2012 and 2011, respectively. At December 31, 2012 and 2011, the Company has $2.0 million and $0.8 million, respectively, included in Accrued expenses in the Consolidated Balance Sheets and $1.0 million included in Other non-current liabilities at December 31, 2012.

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

14.	Retirement Benefits

The Company sponsors several qualified and nonqualified pension plans and other postretirement plans for its employees. The Company uses a measurement date of December 31 for its defined benefit pension plans and post retirement medical plans. The Company employs the measurement date provisions of ASC 715, “Compensation-Retirement Benefits”, which require the measurement date of plan assets and liabilities to coincide with the sponsor’s year end.

The following table provides a reconciliation of the changes in the benefit obligations and fair value of plan assets over the two-year period ended December 31, 2012, and a statement of the funded status at December 31 for both years.


	Pension Benefits												Other Benefits
	2012						2011						2012			2011
	U.S.			Non-U.S.			U.S.			Non-U.S.
	(In thousands)
CHANGE IN BENEFIT OBLIGATION
Obligation at January 1	$	101,511		$	47,763		$	90,102		$	42,245		$	21,073		$	20,068
Service cost		1,756			1,300			1,759			1,078			763			691
Interest cost		4,247			2,206			4,506			2,320			922			1,035
Plan amendments		59			410			—			9			159			—
Benefits paid		(4,097	)		(3,536	)		(4,224	)		(1,703	)		(704	)		(734	)
Actuarial loss		13,202			6,700			10,159			18			3,313			60
Currency translation		—			1,712			—			(906	)		61			(47	)
Curtailments/settlements		(5,490	)		—			(791	)		—			—			—
Acquisition		—			—			—			4,702			—			—

Obligation at December 31	$	111,188		$	56,555		$	101,511		$	47,763		$	25,587		$	21,073

CHANGE IN PLAN ASSETS
Fair value of plan assets at January 1	$	59,619		$	16,914		$	58,147		$	17,400		$	—		$	—
Actual return on plan assets		6,177			1,944			(459	)		(720	)		—			—
Employer contributions(1)		17,287			3,514			6,946			1,569			704			734
Benefits paid		(4,097	)		(3,536	)		(4,224	)		(1,703	)		(704	)		(734	)
Currency translation		—			810			—			(57	)		—			—
Settlements		(4,408	)		—			(791	)		—			—			—
Other		—			14			—			425			—			—

Fair value of plan assets at December 31	$	74,578		$	19,660		$	59,619		$	16,914		$	—		$	—

Funded status at December 31	$	(36,610	)	$	(36,894	)	$	(41,892	)	$	(30,849	)	$	(25,587	)	$	(21,073	)
COMPONENTS ON THE CONSOLIDATED BALANCE SHEETS
Current liabilities	$	(588	)	$	(743	)	$	(602	)	$	(733	)	$	(907	)	$	(937	)
Noncurrent liabilities		(36,022	)		(36,151	)		(41,290	)		(30,116	)		(24,680	)		(20,136	)

Net liability at December 31	$	(36,610	)	$	(36,894	)	$	(41,892	)	$	(30,849	)	$	(25,587	)	$	(21,073	)

(1)	Includes $10.0 million discretionary contribution to U.S. plan in 2012.

The accumulated benefit obligation (ABO) for all defined benefit pension plans was $160.7 million and $143.0 million at December 31, 2012 and 2011, respectively.

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

The weighted average assumptions used in the measurement of the Company’s benefit obligation at December 31, 2012 and 2011 were as follows:


	U.S. Plans						Non-U.S. Plans
	2012			2011			2012			2011
Discount rate		3.56	%		4.45	%		3.91	%		4.68	%
Rate of compensation increase		3.94	%		3.90	%		2.99	%		2.96	%

The pretax amounts recognized in Accumulated other comprehensive income (loss) as of December 31, 2012 and 2011 were as follows:


	Pension Benefits								Other Benefits
	2012				2011				2012			2011
	U.S.		Non-U.S.		U.S.		Non-U.S
	(In thousands)
Prior service cost (credit)	$	275	$	330	$	419	$	127	$	(2,325	)	$	(2,697	)
Net loss		51,240		15,496		49,509		8,781		5,279			2,198

Total	$	51,515	$	15,826	$	49,928	$	8,908	$	2,954		$	(499	)

The amounts in Accumulated other comprehensive income (loss) as of December 31, 2012, that are expected to be recognized as components of net periodic benefit cost during 2013 are as follows:


	U.S. Pension Benefit Plans		Non-U.S. Pension Benefit Plans		Other Benefit Plans			Total
	(In thousands)
Prior service cost (credit)	$	104	$	26	$	(373	)	$	(243	)
Net loss		6,327		935		396			7,658

Total	$	6,431	$	961	$	23		$	7,415

The following tables provide the components of, and the weighted average assumptions used to determine, the net periodic benefit cost for the plans in 2012, 2011 and 2010:


	Pension Benefits
	2012						2011						2010
	U.S.			Non-U.S.			U.S.			Non-U.S.			U.S.			Non-U.S.
	(In thousands)
Service cost	$	1,756		$	1,300		$	1,759		$	1,078		$	1,665		$	719
Interest cost		4,247			2,206			4,506			2,320			4,525			2,148
Expected return on plan assets		(4,687	)		(1,035	)		(4,755	)		(1,117	)		(4,396	)		(945	)
Net amortization		5,376			589			4,855			442			4,401			302

Net periodic benefit cost	$	6,692		$	3,060		$	6,365		$	2,723		$	6,195		$	2,224


	Other Benefits
	2012		2011			2010
	(In thousands)
Service cost	$	763	$	691		$	528
Interest cost		922		1,035			1,008
Net amortization		11		(156	)		(370	)

Net periodic benefit cost	$	1,696	$	1,570		$	1,166

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)


	U.S. Plans									Non-U.S. Plans
	2012			2011			2010			2012			2011			2010
Discount rate		4.45	%		5.20	%		5.80	%		4.68	%		5.35	%		5.88	%
Expected return on plan assets		8.00	%		8.25	%		8.50	%		5.90	%		6.17	%		6.28	%
Rate of compensation increase		3.90	%		3.90	%		3.89	%		2.96	%		3.37	%		3.35	%

The following table provides pretax amounts recognized in Accumulated other comprehensive income (loss) in 2012:


	Pension Benefits
	U.S.			Non-U.S.			Other Benefits
	(In thousands)
Net loss in current year	$	(10,630	)	$	(5,778	)	$	(3,314	)
Prior service cost		(58	)		(206	)		(159	)
Amortization of prior service cost (credit)		105			9			(214	)
Amortization of net loss		5,271			580			225
Exchange rate effect on amounts in OCI		—			(516	)		8

Total	$	(5,312	)	$	(5,911	)	$	(3,454	)

The discount rates for our plans are derived by matching the plan’s cash flows to a yield curve that provides the equivalent yields on zero-coupon bonds for each maturity. The discount rate selected is the rate that produces the same present value of cash flows.

In selecting the expected rate of return on plan assets, the Company considers the historical returns and expected returns on plan assets. The expected returns are evaluated using asset return class, variance and correlation assumptions based on the plan’s target asset allocation and current market conditions.

Prior service costs are amortized on a straight-line basis over the average remaining service period of active participants. Gains and losses in excess of 10% of the greater of the benefit obligation or the market value of assets are amortized over the average remaining service period of active participants.

Costs of defined contribution plans were $7.9 million, $7.8 million and $7.0 million for 2012, 2011 and 2010, respectively.

The Company, through its subsidiaries, participates in certain multiemployer pension plans covering approximately 400 participants under U.S. collective bargaining agreements. None of these plans are considered individually significant to the Company as contributions to these plans totaled $1.0 million, $1.0 million, and $0.9 million for 2012, 2011, and 2010, respectively.

For measurement purposes, a 7.46% weighted average annual rate of increase in the per capita cost of covered health care benefits was assumed for 2012. The rate was assumed to decrease gradually each year to a rate of 4.49% for 2027, and remain at that level thereafter. Assumed health care cost trend rates have a significant effect on the amounts reported for the health care plans. A 1% increase in the assumed health care cost trend rates would increase the service and interest cost components of the net periodic benefit cost by $0.2 million and the health care component of the accumulated postretirement benefit obligation by $2.0 million. A 1% decrease in the assumed health care cost trend rate would decrease the service and interest cost components of the net periodic benefit cost by $0.2 million and the health care component of the accumulated postretirement benefit obligation by $1.7 million.

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Plan Assets

The Company’s pension plan weighted average asset allocations at December 31, 2012 and 2011, by asset category, were as follows:


	2012			2011
Equity securities		68	%		65	%
Fixed income securities		32			35

Total		100	%		100	%

The following tables summarize the basis used to measure defined benefit plans’ assets at fair value at December 31, 2012 and 2011:


	Basis of Fair Value Measurement
	Outstanding Balances		Level 1		Level 2		Level 3
As of December 31, 2012	(In thousands)
Equity	$	19,779	$	19,779	$	—	$	—
Absolute return funds(1)
U.S.		45,555		45,555		—		—
Non U.S.		26,685		18,898		7,787		—
Other(2)		2,219		2,219		—		—

	$	94,238	$	86,451	$	7,787	$	—


	Basis of Fair Value Measurement
	Outstanding Balances		Level 1		Level 2		Level 3
As of December 31, 2011		(In thousands)
Equity	$	14,968	$	14,968	$	—	$	—
Absolute return funds(1)
U.S.		38,449		38,449		—		—
Non U.S.		21,709		16,520		5,189		—
Other(2)		1,015		1,015		—		—

	$	76,141	$	70,952	$	5,189	$	—

(1)	Primarily funds invested by managers that have a global mandate with the flexibility to allocate capital broadly across a wide range of asset classes and strategies including, but not limited to equities, fixed income, commodities, interest rate futures, currencies and other securities to outperform an agreed benchmark with specific return and volatility targets.

(2)	Primarily cash and cash equivalents.

Equities that are valued using quoted prices are valued at the published market prices. Equities in a common collective trust or a registered investment company that are valued using significant other observable inputs are valued at the net asset value (“NAV”) provided by the fund administrator. The NAV is based on value of the underlying assets owned by the fund minus its liabilities. Fixed income securities that are valued using significant other observable inputs are valued at prices obtained from independent financial service industry-recognized vendors.

IDEX CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)

Investment Policies and Strategies

The investment objectives of the Company’s plan assets are to earn the highest possible rate of return consistent with the tolerance for risk as determined periodically by the Company in its role as a fiduciary. The general guidelines of asset allocation of fund assets are that “equities” will represent from 55% to 75% of the market value of total fund assets with a target of 66%, and “fixed income” obligations, including cash, will represent from 25% to 45% with a target of 34%. The term “equities” includes common stock, convertible bonds and convertible stock. The term “fixed income” includes preferred stock and/or contractual payments with a specific maturity date. The Company strives to maintain asset allocations within the designated ranges by conducting periodic reviews of fund allocations and plan liquidity needs, and rebalancing the portfolio accordingly. The total fund performance is monitored and results measured using a 3- to 5-year moving average against long-term absolute and relative return objectives to meet actuarially determined forecasted benefit obligations. No restrictions are placed on the selection of individual investments by the qualified investment fund managers. The performance of the investment fund managers is reviewed on a regular basis, using appointed professional independent advisors. As of December 31, 2012 and 2011, there were no shares of the Company’s stock held in plan assets.

Cash Flows

The Company expects to contribute approximately $7.0 million to its defined benefit plans and $0.9 million to its other postretirement benefit plans in 2013. The Company also expects to contribute approximately $8.6 million to its defined contribution plan and $7.0 million to its 401(k) savings plan in 2013.

Estimated Future Benefit Payments

The future estimated benefit payments for the next five years and the five years thereafter are as follows: 2013 — $12.8 million; 2014 — $10.2 million; 2015 — $9.8 million; 2016 — $9.9 million; 2017 — $10.4 million; 2018 to 2022 — $56.7 million

15.	Quarterly Results of Operations (Unaudited)

The following table summarizes the unaudited quarterly results of operations for the years ended December 31, 2012 and 2011.


	2012 Quarters									2011 Quarters
	First		Second		Third		Fourth(1)			First		Second		Third		Fourth
	(In thousands, except per share amounts)
Net sales	$	489,417	$	494,144	$	479,859	$	490,838		$	427,089	$	453,798	$	476,881	$	480,683
Gross profit		202,889		203,113		194,840		202,858			178,700		184,839		181,532		193,602
Operating income (loss)		84,569		88,650		80,588		(125,589	)		77,721		79,629		71,305		76,001
Net income (loss)		52,171		54,351		50,127		(119,019	)		47,951		50,182		48,336		47,388
Basic EPS	$	.63	$	.65	$	.60	$	(1.45	)	$	.58	$	.61	$	.58	$	.57
Diluted EPS	$	.62	$	.65	$	.60	$	(1.45	)	$	.57	$	.60	$	.58	$	.57
Basic weighted average shares outstanding		82,804		83,180		82,482		82,296			81,430		82,151		82,402		82,596
Diluted weighted average shares outstanding		83,902		84,090		83,370		82,296			83,248		83,778		83,586		83,573

(1)	Fourth quarter 2012 includes a $198.5 million asset impairment charge.

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Shareholders of IDEX Corporation

We have audited the accompanying consolidated balance sheets of IDEX Corporation and subsidiaries (the “Company”) as of December 31, 2012 and 2011, and the related consolidated statements of operations, comprehensive income, shareholders’ equity, and cash flows for each of the three years in the period ended December 31, 2012. These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the consolidated financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, such consolidated financial statements present fairly, in all material respects, the consolidated financial position of IDEX Corporation and subsidiaries as of December 31, 2012 and 2011, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2012, in conformity with accounting principles generally accepted in the United States of America.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the Company’s internal control over financial reporting as of December 31, 2012, based on the criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February 21, 2013, expressed an unqualified opinion on the Company’s internal control over financial reporting.




Deloitte & Touche LLP

Chicago, Illinois

February 21, 2013

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Shareholders of IDEX Corporation

We have audited the internal control over financial reporting of IDEX Corporation and subsidiaries (the “Company”) as of December 31, 2012, based on criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. As described in Management’s Report on Internal Control Over Financial Reporting, management excluded from its assessment the internal control over financial reporting at Precision Photonics Corporation (“PPC”), which was acquired on April 11, 2012, ERC, which was acquired on April 30, 2012, and Matcon Group Ltd (“Matcon”), which was acquired on July 20, 2012. These exclusions constitute 6.0% and 3.8% of net and total assets, respectively, and 1.7% of net sales, of the consolidated financial statement amounts as of and for the year ended December 31, 2012. Accordingly, our audit did not include the internal control over financial reporting at PPC, ERC and Matcon. The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

A company’s internal control over financial reporting is a process designed by, or under the supervision of, the company’s principal executive and principal financial officers, or persons performing similar functions, and effected by the company’s board of directors, management, and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America (“generally accepted accounting principles”). A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of the inherent limitations of internal control over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may not be prevented or detected on a timely basis. Also, projections of any evaluation of the effectiveness of the internal control over financial reporting to future periods are subject to the risk that the controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2012, based on the criteria established in Internal Control — Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission.

We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated financial statements as of and for the year ended December 31, 2012, of the Company and our report dated February 21, 2013, expressed an unqualified opinion on those consolidated financial statements.




Deloitte & Touche LLP

Chicago, Illinois

February 21, 2013

MANAGEMENT’S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING

Internal control over financial reporting refers to the process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America, and includes those policies and procedures that:

	•		Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;

	•		Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and

	•		Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

Internal control over financial reporting cannot provide absolute assurance of achieving financial reporting objectives because of its inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk. Management is responsible for establishing and maintaining effective internal control over financial reporting for the Company. Management has used the framework set forth in the report entitled “Internal Control — Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission to assess the effectiveness of the Company’s internal control over financial reporting. Management has concluded that the Company’s internal control over financial reporting was effective as of December 31, 2012.

The Company completed the acquisitions of PPC in April 2012, ERC in April 2012 and Matcon in July 2012. Due to the timing of the acquisitions, management has excluded these acquisitions from our evaluation of effectiveness of internal controls over financial reporting. This exclusion represented 1.7% of total sales, 6.0% of net assets and 3.8% of total assets for the year ended December 31, 2012.

The effectiveness of the Company’s internal control over financial reporting as of December 31, 2012, has been audited by Deloitte & Touche LLP, an independent registered public accounting firm, as stated in their report which appears herein.




Andrew K. Silvernail
Chairman of the Board, President and Chief Executive Officer




Heath A. Mitts
Vice President and Chief Financial Officer

Lake Forest, Illinois

February 21, 2013

Previous: Item 7A. Quantitative and Qualitative Disclosures About Market Risk. · Next: Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.